CSIMarket Company Name, Ticker, Customers, else..
 
Synlogic Inc   (NASDAQ: SYBX)
Other Ticker:  
 
 
Price: $1.5200 $-0.01 -0.654%
Day's High: $1.6 Week Perf: 7.79 %
Day's Low: $ 1.49 30 Day Perf: 6.29 %
Volume (M): 51 52 Wk High: $ 5.12
Volume (M$): $ 78 52 Wk Avg: $1.92
Open: $1.60 52 Wk Low: $1.22



 Market Capitalization (Millions $) 19
 Shares Outstanding (Millions) 12
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -56
 Cash Flow (TTM) (Millions $) -27
 Capital Exp. (TTM) (Millions $) 0

Synlogic Inc
Synlogic Inc is a biotechnology company that focuses on the development of synthetic biotics. These synthetic biotics are engineered to perform specific functions within the body, such as the treatment of diseases or the restoration of missing or impaired metabolic functions. The company aims to provide novel and effective therapies for a range of diseases by harnessing the power of synthetic biology. Synlogic Inc's synthetic biotics have the potential to address a variety of conditions, including metabolic disorders, cancer, and autoimmune diseases. Through their innovative approach, the company aims to transform the treatment landscape and improve the lives of patients.


   Company Address: PO Box Winchester 1890 MA
   Company Phone Number: 401-9975   Stock Exchange / Ticker: NASDAQ SYBX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
INVA   -0.37%    
ME        0.83% 
PFE   -1.83%    
TEVA   -0.43%    
VRTX        1.82% 
VTRS   -1.09%    
• View Complete Report
   



Stock Market Announcement

Synlogic Adopts Limited Duration Stockholders Rights Plan, Engages Ladenburg Thalmann for Strategic Review Process

Published Tue, Feb 20 2024 5:15 PM UTC

Synlogic Adopts Limited Duration Stockholders Rights Plan, Engages Ladenburg Thalmann as Financial Advisor
CAMBRIDGE, Mass. - Synlogic, a clinical-stage biotechnology company, has recently announced the adoption of a Limited Duration Stockholders Rights Plan. In addition, the company has engaged Ladenburg Thalmann as its financial advisor to assist with a previously anno...
Clinical Study

Synlogic Halts Synpheny-3 Clinical Trial and Overhauls Strategy to Prioritize Promising Programs

Published Thu, Feb 8 2024 9:15 PM UTC

Synlogic Discontinues Synpheny-3 Study and Provides Strategic Corporate Update Synlogic, a leading synthetic biotechnology company, recently made the decision to discontinue its clinical trial for Synpheny-3, following an internal review of the preliminary data that indicated a low likelihood of achieving the primary endpoint. This significant announcement has led to a shift...
Clinical Study

Synlogic's SYNB1353: A Potential Game-Changer in the Treatment of Classical Homocystinuria - Early Insights and Impacts.

Published Fri, Feb 2 2024 5:00 PM UTC

Recent innovations in medicine often overturn the conventional understanding of disease management and patient care, and a remarkable case in point is the use of engineered bacteria as therapeutic agents. This fascinating new frontier is under sharp focus with Synlogic's publication of preclinical and clinical data for their experimental therapeutic SYNB1353.With the primary...
Clinical Study

Shifting Landscapes: Synlogic's Potential Expansion of PKU Treatment Trial to Adolescents An Examination of Therapeutic Innovation

Published Thu, Jan 4 2024 12:00 PM UTC

As the landscape of innovation and technology within the realm of medicine continuously evolves with unprecedented velocity, it is enthralling to bear witness to the disruptive advancements brought to light by dedicated researchers. In the vanguard of these change-makers is Synlogic, a clinical-stage company that leads the charge in engineering bacteria to deliver therapeuti...
Contract

Synlogic Bagged Contract from Air Force, Reflecting the Company's Synthetic Biology Prowess despite Revenue Dips

Published Wed, Dec 27 2023 12:00 PM UTC

Synthetic biology leader, Synlogic Inc., has recently announced a significant contract with the Air Force Research Laboratory. This recent alignment underscores the company's prowess in process development and manufacturing of therapeutics hinged on synthetic biology. However, this positive development also enlisted alongside an unfortunate decline in company revenues in the...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com